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Abstract
Aims Maximum oxygen uptake (VO2max) is an essential parameter to assess functional capacity of patients with heart failure
(HF). We aimed to identify clinical factors that determine its value, as they have not been well characterized yet.
Methods We conducted a retrospective, observational, single-centre study of 362 consecutive patients with HF who
underwent cardiopulmonary exercise testing (CPET) as part of standard clinical assessment since 2009–2019. CPET was
performed on treadmill, according to Bruce’s protocol (n = 360) or Naughton’s protocol (n = 2). We performed multivariable
linear regression analyses in order to identify independent clinical predictors associated with peak VO2max.
Results Mean age of study patients was 57.3 ± 10.9 years, mean left ventricular ejection fraction was 32.8 ± 14.2%, and
mean VO2max was 19.8 ± 5.2 mL/kg/min. Eighty-nine (24.6%) patients were women, and 114 (31.5%) had ischaemic heart
disease. Multivariable linear regression analysis identified six independent clinical predictors of VO2max, including NYHA class
(B coefficient = 2.585; P < 0.001), age (B coefficient per 1 year = 0.104; P < 0.001), tricuspid annulus plane systolic
excursion (B coefficient per 1 mm = +0.209; P < 0.001), body mass index (B coefficient per 1 kg/m2 = 0.172; P = 0.002),
haemoglobin (B coefficient per 1 g/dL = +0.418; P = 0.007) and NT-proBNP (B coefficient per 1000 pg/mL = 0.142; P = 0.019).
Conclusions The severity of HF (NYHA class, NT-proBNP) as well as age, body composition and haemoglobin levels influence
significantly exercise capacity. In patients with HF, the right ventricular systolic function is of greater importance for the
physical capacity than the left ventricular systolic function.
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Introduction
Exercise intolerance is one of the main symptoms of heart
failure (HF) and a major factor conditioning a patient’s
quality of life.1 Moreover, the aetiopathogenesis of exercise
intolerance is multifactorial, because it involves central
factors2 related to cardiopulmonary system disorder and also
peripheral factors related to both the vascular and musculo-
skeletal systems.3,4
Maximum oxygen uptake (VO2max) or aerobic power is the
best single parameter to measure a person’s capacity to
perform aerobic exercise. This parameter is defined as the
maximum amount of oxygen that the body can absorb,
transport and consume per unit of time.5
In clinical practice, VO2max is determined in a protocolized
way using the cardiopulmonary exercise testing (CPET) on a
cycle ergometer or on a treadmill.6 This parameter represents
an objective estimation of the functional capacity in patients
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with cardiovascular disease, and, in addition, it allows
prognostic stratification in patients with HF, having been
included in some of the most used mortality risk prediction
scores such as HFSS7 or UCLA four-variable risk score.8 In this
sense, one of the main uses of VO2max is to serve as a guide
for the selection of candidates for advanced therapies,
including heart transplant.9 CPET allows the additional
determination of other parameters that complement the
diagnostic and prognostic value of VO2max such as VO2peak,
VO2max/percentage of predicted VO2 ratio (%pp VO2),
VO2max/body mass index (BMI) ratio, pulmonary ventilator ef-
ficiency slope ratio (VE) /maximum carbon dioxide uptake
(VCO2) and oxygen uptake efficiency slope (OUES).
11
To date, there is little information on the clinical factors
that determine the exercise capacity of patients with HF12;
the role of some co-morbidities such as obesity, anaemia or
chronic kidney disease (CKD) in this regard has not been
completely clarified.13
The main objective of this study was to identify clinical
factors associated with VO2max in a cohort of consecutive
patients with HF who underwent CPET at a Spanish university
hospital. As a secondary objective, we set out to evaluate the
impact of the main co-morbidities associated with HF on
VO2max.
Methods
Study design and population
We carried out a retrospective observational study that
included patients with HF seen in the specialized cardiology
unit of the Complexo Hospitalario Universitario de A Coruña
(CHUAC) who underwent a CPET between 2009 and 2019 as
part of the standard clinical protocol of diagnostic and
prognostic evaluation. For the purposes of this study, the
follow-up of the vital status of the patients was extended
until 13 March 2020.
The study protocol was approved by A Coruña and Ferrol
Ethics Committee in Clinical Research.
Cardiopulmonary exercise testing
All CPET tests of the patients included in the study were
carried out in the laboratory of the Cardiac Imaging and
Functional Unit of the Cardiology Service of CHUAC using a
treadmill and the Bruce or Naughton protocols, depending
on the specific characteristics of the patient.14,15 In cases
where the patient had more than one CPET during the study
period, the first one performed was considered.
Sources of data
The data presented in this manuscript were obtained
from the clinical data system of the Heart Failure Unit
of the CHUAC (Intelligent Heart Failure Monitoring System,
SiMON-IC), complemented with the individual review of
medical records, both in electronic and in paper formats.
Variable definition
For this study, the demographic, clinical, analytical and
functional variables related to common functional studies
were collected to describe a population of patients with HF,
as well as specific variables in relation to CPET. The main
variable of the study was VO2max determined by CPET.
Regarding co-morbidities, anaemia was defined as
any haemoglobin value < 13 g/dL in men and <12 g/dL
in women, CKD as a glomerular filtration rate (GFR)
< 60 mL/min/m2 and obesity as a BMI ≥ 30 kg/m2.
Statistical analysis
In this study, quantitative variables are described by
mean ± standard deviation, whereas variable categories are
expressed as absolute and relative frequency. The chi-square
test and Student’s t-test were used to compare groups, de-
pending on the variable being analysed.
A multivariable linear regression model through backward
steps was used to identify baseline clinical variables that are
independently associated with VO2max by selecting a Pout
value < 0.05. Candidate variables for entering the first step
of the backward stepwise analysis were those who showed
a statistically significant or near-significant univariate associa-
tion with VO2max (univariate P value < 0.15). Variables with
>20% missing values were not considered for these analyses.
A comparison of the VO2max value and VO2max/%pp VO2
ratio was proposed in seven subgroups selected according
to the presence of clinical characteristics of special interest,
such as age (≥60 years vs. <60 years), sex, left ventricular
ejection fraction (LVEF) (<40% vs. ≥40%), GFR (<60 mL/min
vs. ≥60 mL/min), BMI (<30 vs. ≥30), anaemia and tricuspid
annular plane systolic excursion (TAPSE) (<15 mm vs.
≥15 mm).
A significance level P < 0.05 was assumed for all the con-
trasts proposed. The analysis was performed with SPSS 20.
Results
Study population
Three hundred sixty-two patients were studied, of which 89
(24.6%) were female. The mean age of the population was
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57.3 +/ 10.9 years. Most (n = 203, 56.1%) of the patients
were in New York Heart Association (NYHA) functional class
II. Anaemia was observed in 117 (32.3%), arterial hyperten-
sion in 161 (44.5%), ischaemic heart disease in 114 (31.5%),
CKD in 111 (30.7%), and obesity in 118 (32.6%). Table 1
provides baseline clinical characteristics, co-morbidity and
laboratory values in the study patients.
Table 2 shows the data referring to complementary studies
and pharmacological treatment. The majority (n = 240,
66.2%) was in sinus rhythm and almost a quarter in atrial
fibrillation (n = 88, 24.3%). A total of 261 (72.1%) patients
presented HF with reduced LVEF (<40%), 58 (16%) patients
presented HF with mid-range LVEF (40%–49%), and 43
(11.9%) patients presented HF with preserved LVEF (≥50%).
Beta-blockers were prescribed to 330 (91.2%) patients,
angiotensin-converting enzyme (ACE) inhibitors or angioten-
sin II receptor blockers (ARB) to 248 (68.5%), sacubitril-
valsartan to 30 (8.3%), and mineralocorticoid receptor
antagonists to 265 (73.2%). Overall, 181 (50%) patients
carried a defibrillator, 49 (13.5%) patients carried a cardiac
resynchronization therapy-defibrillator device, and 5 (1.4%)
patients carried a cardiac resynchronization therapy-
pacemaker device.
Cardiopulmonary exercise testing
All CPET studies were performed according to Bruce’s
protocol, except two, which were performed according to
Naughton’s one. The CPET parameters are shown in Table 3.
The mean VO2max achieved was 19.8 mL/kg/min (±5.2 SD),
with a mean VO2max/%pp VO2 ratio of 75.9% (±21, 0 SD)
Table 1 Baseline clinical characteristics of 362 patients with heart
failure who underwent cardiopulmonary exercise test
Demographics and clinical statusa
Age (years), mean ± SD 57.3 ± 10.9
Male sex, n (%) 273 (75.4%)
Body mass index (kg/m2), mean ± SD 28.1 ± 4.8
Systolic blood pressure (mm Hg), mean ± SD 112.1 ± 17.3
Resting heart rate (beats per min), mean ± SD 67.3 ± 11.5





Co-morbidities and aetiology b
Hypertension, n (%) 161 (44.5%)
Anaemia, n (%) 117 (32.3%)
Ischemic heart disease, n (%) 114 (31.5%)
Type 2 diabetes mellitus, n (%) 98 (27.1%)
Chronic kidney disease, n (%) 111 (30.7%)
COPD, n (%) 14 (3.9%)
Obesity, n (%) 118 (32.6%)
Laboratory variablesc
Creatinine (mg/dL), mean ± SD 1.3 ± 0.9
Glucose (mg/dL), mean ± SD 111.9 ± 47.2
Urea (mg/dL), mean ± SD 65.7 ± 33.3
Sodium (mEq/L), mean ± SD 139 ± 6.6
GGT (u/L), mean ± SD 76.2 ± 99.7
ALT (u/L), mean ± SD 30.7 ± 28.4
Bilirubin (mg/dL), mean ± SD 0.8 ± 0.6
Uric acid (mg/dL), mean ± SD 7.8 ± 2.2
LDH (u/L), mean ± SD 383.2 ± 154.8
Albumin (g/dL), mean ± SD 4.3 ± 0.3
NT-proBNP (pg/mL), mean ± SD 2794.1 ± 4165.1
Haemoglobin (g/L), mean ± SD 13.7 ± 1.7
Haematocrit (%), mean ± SD 40.8 ± 5.8
Ferritin (ng/mL), mean ± SD 170.9 ± 144.6
ALT, alanine aminotransferase; COPD, chronic obstructive pulmo-
nary disease; GGT, gamma-glutamyl transferase; LDH, lactate dehy-
drogenase; NT-proBNP, N-terminal pro-brain natriuretic peptide;
NYHA, New York Heart Association; SD, standard Deviation.
aMissing values: body mass index (n= 3), resting heart rate (n= 1),
systolic blood pressure (n = 1).
bMissing values: chronic kidney disease (n = 3), obesity (n = 5).
cMissing values: creatinine (n = 1), glucose (n = 2), urea (n = 13),
sodium (n= 2), GGT (n= 46), ALT (n= 35), bilirubin (n= 69), uric
acid (n = 132), LDH (n = 233), albumin (n = 247), NT-proBNP
(n = 48), ferritin (n = 339).
Table 2 Baseline electrocardiography, echocardiography, implant-
able electrical devices and treatments (n = 362)
ECG cardiac rhythm at rest
Sinus rhythm, n (%) 241 (66.6%)
Atrial fibrillation, n (%) 88 (24.3%)
Atrial flutter, n (%) 4 (1.1%)
Paced rhythm, n (%) 29 (8%)
Implantable electrical devices
ICD, n (%) 181 (50%)
CRT-D, n (%) 49 (13.5%)
CRT-P, n (%) 5 (1.4%)
Pacemaker, n (%) 12 (3.3%)
No device, n (%) 115 (31.8%)
Echocardiographya
LVESD (cm), mean ± SD 5.2 ± 1.3
LVEDD (cm), mean ± SD 6.2 ± 1
LVEF (%), mean ± SD 32.8 ± 14.2
TAPSE (mm), mean ± SD 17.4 ± 5.3
Medications
Beta-blockers, n (%) 341 (94.2%)
Diuretics, n (%) 308 (85.1%)
ACEI or ARB, n (%) 248 (68.5%)
Sacubitril-valsartan, n (%) 30 (8.3%)
MRA, n (%) 265 (73.2%)
Ivabradine, n (%) 36 (9.9%)
Digoxin, n (%) 20 (5.5%)
Amiodarone, n (%) 25 (6.9%)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; CRT-D, cardiac resynchronization therapy with
defibrillator; CRT-P, cardiac resynchronization therapy with
pacemaker; ECG, electrocardiogram; ICD, implantable
cardioverter-defibrillator; LVEDD, left ventricular end-diastolic
diameter; LVEF, left ventricular ejection fraction; LVESD, left
ventricular end-systolic diameter; MRA, mineralocorticoid receptor
antagonist; TAPSE, tricuspid annular plane systolic excursion.
aMissing values: LVEDD (n = 28), LVESD (n = 56), TAPSE (n = 74).
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and a mean duration of exercise of 8.4 (±3.9 SD) min. VO2max
was <14 mL/kg/min in 45 (12.4%) patients.
Determining factors of VO2max
Table 4 shows the results of the linear regression analyses
used to identify the clinical factors that determine VO2max
value in the study patients. Twelve variables that showed a
univariate P value < 0.15 were selected for entering the first
step of the backward stepwise process. Among them, six
variables remained as independent predictors of VO2max in
the final multivariable linear regression model.
Older age (B coefficient for 1 year = 0.104; P < 0.001),
worse NYHA functional class (B coefficient for one functional
class 2.585; P < 0.001), higher plasma N-terminal pro-brain
natriuretic peptide (NT-proBNP) value (B coefficient per
1000 pg/mL = 0.142; P = 0.019) and a higher BMI
(B coefficient 0.172; P = 0.002) were statistically signifi-
cantly and independently associated with a lower VO2max.
On the other hand, a higher TAPSE (B coefficient per
1 mm = +0.209; P < 0.001) and a higher haemoglobin plasma
value (B coefficient per 1 g/dL = +0.418; P = 0.007) were
associated, also statistically significant and independently,
with a higher VO2max value.
Univariate linear regression coefficients for all explored
variables are presented in Table S1.
Subgroup analysis
Table 5 shows the comparison of the VO2max values and the
VO2max/%pp VO2 ratio in seven subgroups of patients defined
based on clinical variables of interest.
Male patients presented in absolute terms a higher
VO2max than female patients (20.4 ± 5.3 mL/kg/min vs.
18.1 ± 4.2 mL/kg/min; P = 0.027); however, the VO2max/%pp
VO2 ratio was significantly higher in women (72.8% ± 18.9
vs. 85.4% ± 18.9; P < 0.001).
VO2max in patients with anaemia (16.8 ± 3.9 mL/kg/min)
was significantly lower than that of the rest of the population
(20.3 ± 5.4 mL/kg/min) (P < 0.001); however, VO2max/%pp
VO2 ratio showed no significant differences between these
two groups.
VO2max value was higher in patients under 60
(21.6 ± 5.2 mL/kg/min) compared with those over 60
(17.9 ± 4.7 mL/kg/min; P < 0.001). However, the difference
between both groups in relation to the VO2max/%pp VO2 ratio
did not reach statistical significance (P = 0.087).
Patients without CKD showed a superior response to
exercise than those with CKD, both in VO2max values
(20.1 ± 5.4 mL/kg/min vs. 17.2 ± 4.2 mL/kg/min; P < 0.001)
as in the VO2max/%pp VO2 ratio (77.7 ± 21.9 vs. 71.5 ± 17.9;
P = 0.001).
Table 3 Cardiopulmonary exercise testing parameters in 362
patients with heart failure
CPET parameters
VO2 peak (mL/kg/min), mean ± SD 19.8 ± 5.2
%pp VO2, mean ± SD 75.9 ± 21.0
VE/VCO2, mean ± SD 37.8 ± 8.1
% maximum HR, mean ± SD 77.7 ± 16.3
RER, mean ± SD 1.09 ± 0.1
Exercise time (min), mean ± SD 8.4 ± 3.9
METs, mean ± SD 5.7 ± 2.2
% maximum HR, percentage of maximum predicted heart rate;
% pp VO2, percentage of predicted peak oxygen uptake; CPET,
cardiopulmonary exercise testing; METs, metabolic equivalents of
task; RER, respiratory exchange ratio; VE/VCO2, ventilatory equiva-
lent ratio for carbon dioxide; VO2peak, peak oxygen uptake.
Table 4 Clinical factors associated with peak VO2: multivariable linear regression analysis
Univariate analysisa Multivariate analysisb
B coefficient P B coefficient P
Age (years) 0.259 <0.001 0.104 <0.001
BMI (kg/m2) 0.235 0.131 0.172 0.002
Atrial fibrillation/flutter 2.781 0.106 – –
Hypertension 3.162 0.001 – –
Diabetes mellitus 2.582 0.123 – –
NYHA class 2.184 0.059 2.585 <0.001
Creatinine (mg/dL) 1.228 0.135 – –
Urea (mg/dL) 0.045 0.049 – –
Haemoglobin (g/L) +0.642 0.137 +0.418 0.007
NT-proBNP (1000 pg/mL) 0.328 0.107 0.142 0.019
TAPSE (mm) +0.248 0.002 +0.209 <0.001
Ivabradine use +7.933 0.001 – –
BMI, body mass index; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA; New York Heart Association; TAPSE, tricuspid annular
plane systolic excursion.
aVariables presented are only those that showed a univariate association with VO2 with a P-value < 0.15, as assessed by linear regression.
These 10 variables entered the first step of multivariable backward stepwise linear regression analysis. The complete relationships of
variables assessed, as well as their univariate regression coefficients, are presented as Supporting Information.
bVariables presented are only those that were selected in the final step of multivariable backward stepwise linear regression analysis.
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Patients with a TAPSE ≥ 15 presented a higher VO2max
value (19.9 ± 5.1 vs. 17.5 ± 4.2; P < 0.001) and a higher
VO2max/%pp VO2 ratio (79.4 ± 18.0 vs. 69.1 ± 18.0;
P < 0.001) than patients with TAPSE < 15.
We did not observe statistically significant differences in
VO2max based on the presence or absence of obesity or the
presence or absence of an LVEF > 40%.
Discussion
VO2max is an essential parameter for the functional and
prognostic assessment of patients with HF that depends on
central and peripheral factors. In our research, in which we
have studied a cohort of patients with HF followed in a
specialized cardiology unit, we have identified six
independent clinical predictors of VO2max, including age,
NYHA functional class and the presence of obesity,
haemoglobin and NT-proBNP plasma levels and TAPSE.
The relationship between ageing and a progressive
reduction in exercise capacity is well known. As in our study,
the literature has referenced that younger patients present
higher absolute VO2max values in CPET.
16 This trend towards
a decrease in the theoretical VO2 as age increases may result
in a less prognostic value of VO2max in patients with HF and
older age. Therefore, the use of VO2max/%pp VO2 ratio is rec-
ommended in this subgroup with the intention of, for
example, selecting candidates for advanced therapies.10
The association observed between a higher NYHA
functional class and a lower VO2max value in patients with
HF is evident. The NYHA functional class, although
conditioned by a subjective evaluation, is a good initial
approach to the global symptom burden of patients with
HF17 and has shown a significant prognostic value in these
individuals.18 The findings of lower VO2max values in patients
with higher plasma levels of NT-proBNP are consistent with
the known diagnostic and prognostic value of this biomarker
as an indicator of the degree of congestion and severity
of HF.19
An interesting finding of our study is the independent
association observed between an indicator of right
ventricular function, TAPSE and VO2max. This relationship is
more interesting, if possible, taking into account that in our
series we have not been able to evidence an impact of LVEF
on this parameter. These results seem to suggest that in
patients with HF, the preservation of the contractile function
of the right ventricle would be a more determining factor for
keeping the ability to exercise than the systolic function of
the left ventricle itself. The prognostic importance of the
parameters that assess right ventricular function in patients
with HF, even in those with preserved LVEF, has been
previously demonstrated.20 It should be noted, however, that
a study with a slightly larger sample size than ours, Nadruz
et al.,21 did observe a significant impact of LVEF on VO2max,
so patients with LVEF > 40% had higher values than patients
with LVEF < 40%.
Table 5 Comparison of peak VO2 and % predicted VO2 in selected clinical subgroups
Subgroups
VO2 peak (mL/kg/min)
Mean ± SD P %pp VO2 P
Gender 0.027 <0.001
Female (n = 89) 18.1 ± 4.2 85.4 ± 18.9
Male (n = 273) 20.4 ± 5.3 72.8 ± 20.7
Anaemia <0.001 0.215
Without anaemia (n = 51) 20.3 ± 5.4 76.5 ± 21.9
With anaemia (n = 311) 16.8 ± 3.9 72.7 ± 19.9
Left ventricular ejection fraction (%) 0.690 0.454
LVEF < 40 (n = 261) 20.1 ± 5.2 75.6 ± 21.6
LVEF ≥ 40 (n = 101) 19.6 ± 5.5 77.4 ± 19.6
Chronic kidney diseasea <0.001 0.006
GFR ≥ 60 mL/min/m2 (n = 246) 20.1 ± 5.4 77.7 ± 21.9
GFR < 60 mL/min/m2 (n = 111) 17.2 ± 4.2 71.5 ± 17.9
Age (years) <0.001 0.087
<60 (n = 186) 21.6 ± 5.2 74.1 ± 20.1
≥60 (n = 176) 17.9 ± 4.7 77.9 ± 20.1
Obesityb 0.073 <0.001
BMI < 30 kg/m2 (n = 241) 20.5 ± 5.6 72.4 ± 18.9
BMI ≥ 30 kg/m2 (n = 118) 18.3 ± 5.4 82.8 ± 23.3
Right ventricular functionc 0.001 <0.001
TAPSE < 15 mm (n = 100) 17.5 ± 4.2 69.1 ± 18.0
TAPSE ≥ 15 mm (n = 188) 19.9 ± 5.1 79.4 ± 19.9
%pp VO2, percentage of predicted peak VO2; BMI, body mass index; GFR, glomerular filtration rate; peak VO2, peak oxygen uptake; SD,
standard deviation; TAPSE, tricuspid annular plane systolic excursion.
aMissing data in 3 (0.8%) patients.
bMissing data in 5 (1.4%) patients.
cMissing data in 74 (20.4%) patients.
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Obesity22 and anaemia23 are two frequent co-morbidities
in patients with HF that significantly affect their exercise
capacity. Other authors have previously described an
association between a higher BMI24 or a lower haemoglobin
plasma value25 and a lower VO2max value in CPET. Patients
with anaemia experience a decline in mitochondrial oxidative
function, reduced adenosine triphosphate production and a
decline of the capacity of muscular contraction that affects
notably its exercise tolerance.26
In our study, the univariate analysis showed that patients
with CKD had significantly lower VO2max and VO2max/%pp
VO2 values than patients with preservation of renal function.
CKD is a known factor of poor prognosis and poor functional
capacity in patients with HF, which can affect exercise
capacity through inflammatory mechanisms, loss of muscle
mass and increased oxidative stress.27,28 However, CKD was
not founded as an independent predictor of VO2max in the
multivariable analysis, a result that we attribute, as the most
likely explanation, to its tendency to coexist in the same
patient with other independent risk markers such as age
and advanced NYHA functional class, anaemia or elevated
NT-proBNP, as well as the limited sample size of our study.
The present study has several limitations. Firstly, it is an
observational and retrospective study, so it is exposed to
the typical biases of this type of research. Secondly, CPETs
were performed within the framework of routine clinical
care, and not according to a predefined research protocol.
Finally, it should be noted that the sample size of the study,
even being relevant, may have been insufficient to detect
as statistically significant other risk associations that do may
be clinically relevant
Conclusions
The severity HF (NYHA class, NT-proBNP) and age, body
composition and haemoglobin levels influence significantly
exercise capacity. In patients with HF, the right ventricular
systolic function is of greater importance for the physical
capacity than the left ventricular systolic function.
Our work highlights the importance of associated clinical
conditions as determinants of exercise tolerance in patients
with HF and reinforces the importance of appropriate
handling of co-morbidities to improve functional capacity in
these individuals.
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